

# Darren R Feldman

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8341688/darren-r-feldman-publications-by-citations.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

158  
papers

7,093  
citations

40  
h-index

81  
g-index

172  
ext. papers

8,963  
ext. citations

5.6  
avg, IF

5.45  
L-index

#	Paper	IF	Citations
158	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. <i>Nature Medicine</i> , <b>2017</b> , 23, 703-713	50.5	1638
157	Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 591-597	2.2	434
156	High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 3466-73	2.2	300
155	Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 1432-9	2.2	268
154	Medical treatment of advanced testicular cancer. <i>JAMA - Journal of the American Medical Association</i> , <b>2008</b> , 299, 672-84	27.4	253
153	Testicular cancer survivorship: research strategies and recommendations. <i>Journal of the National Cancer Institute</i> , <b>2010</b> , 102, 1114-30	9.7	215
152	Integrated Molecular Characterization of Testicular Germ Cell Tumors. <i>Cell Reports</i> , <b>2018</b> , 23, 3392-3406	10.6	200
151	Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. <i>European Journal of Cancer</i> , <b>2018</b> , 94, 115-125	7.5	179
150	Testicular cancer. <i>Nature Reviews Disease Primers</i> , <b>2018</b> , 4, 29	51.1	164
149	TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1706-13	2.2	150
148	Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2712-20	2.2	123
147	Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4000-4007	2.2	110
146	Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. <i>Cancer</i> , <b>2012</b> , 118, 1868-76	6.4	100
145	Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 3712-20	12.9	75
144	Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma. <i>Investigational New Drugs</i> , <b>2012</b> , 30, 335-40	4.3	73
143	Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106,	9.7	72
142	Natural immunity to pluripotency antigen OCT4 in humans. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2010</b> , 107, 8718-23	11.5	71

141	Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2011</b> , 34, 454-9	2.7	68
140	Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition. <i>PLoS ONE</i> , <b>2012</b> , 7, e51563	3.7	67
139	The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , <b>2018</b> , 6, 758-765	12.5	66
138	Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. <i>JAMA Oncology</i> , <b>2018</b> , 4, 1228-1235	13.4	66
137	Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities. <i>Oncologist</i> , <b>2011</b> , 16, 543-53	5.7	65
136	A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma. <i>Oncologist</i> , <b>2016</b> , 21, 787-8	5.7	64
135	Identification and validation of a gene expression signature that predicts outcome in adult men with germ cell tumors. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 5240-7	2.2	62
134	Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2019</b> , 17, 1529-1554	7.3	62
133	Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1211-1222	2.2	57
132	Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies. <i>Annals of Oncology</i> , <b>2014</b> , 25, 663-668	10.3	57
131	Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors. <i>Investigational New Drugs</i> , <b>2010</b> , 28, 523-8	4.3	55
130	Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3846-3853	2.2	55
129	Revisiting DNA damage repair, p53-mediated apoptosis and cisplatin sensitivity in germ cell tumors. <i>International Journal of Developmental Biology</i> , <b>2013</b> , 57, 273-80	1.9	54
128	Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options--An Analysis From the Global Germ Cell Cancer Group. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 345-51	2.2	49
127	Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1505-1512	2.2	49
126	Variants in and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 3325-3333	12.9	47
125	Pediatric and Adolescent Extracranial Germ Cell Tumors: The Road to Collaboration. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3018-28	2.2	45
124	Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3525-3528	2.2	45

123	Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design. <i>Cancer</i> , <b>2012</b> , 118, 981-6	6.4	44
122	The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis. <i>Investigational New Drugs</i> , <b>2012</b> , 30, 1773-81	4.3	44
121	Is high dose therapy superior to conventional dose therapy as initial treatment for relapsed germ cell tumors? The TIGER Trial. <i>Journal of Cancer</i> , <b>2011</b> , 2, 374-7	4.5	43
120	Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 5757-5768	12.9	40
119	Long-term response to sunitinib therapy for metastatic renal cell carcinoma. <i>Clinical Genitourinary Cancer</i> , <b>2013</b> , 11, 297-302	3.3	40
118	The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis. <i>European Journal of Cancer</i> , <b>2012</b> , 48, 340-6	7.5	40
117	Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 7405-11	12.9	40
116	Late cardiovascular toxicity following chemotherapy for germ cell tumors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2012</b> , 10, 537-44	7.3	40
115	A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors. <i>Investigational New Drugs</i> , <b>2013</b> , 31, 1016-22	4.3	38
114	Fertility preservation strategies for male patients with cancer. <i>Nature Reviews Urology</i> , <b>2013</b> , 10, 463-72	5.5	35
113	Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, e987-e994	3.3	34
112	Clinical outcomes of local and metastatic testicular sex cord-stromal tumors. <i>Journal of Urology</i> , <b>2014</b> , 192, 415-9	2.5	34
111	Response to Nivolumab in a Patient With Metastatic Clear Cell Renal Cell Carcinoma and End-stage Renal Disease on Dialysis. <i>European Urology</i> , <b>2016</b> , 70, 1082-1083	10.2	33
110	Safety and efficacy of targeted therapy for renal cell carcinoma with brain metastasis. <i>Clinical Genitourinary Cancer</i> , <b>2015</b> , 13, 59-66	3.3	29
109	Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma. <i>European Urology Focus</i> , <b>2017</b> , 3, 421-427	5.1	29
108	Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment Outcomes. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, e678-e688	3.3	28
107	Development of a risk stratification system to guide treatment for female germ cell tumors. <i>Gynecologic Oncology</i> , <b>2015</b> , 138, 566-72	4.9	27
106	Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma. <i>European Urology Focus</i> , <b>2019</b> , 5, 642-649	5.1	27

105	Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors. <i>Cancer</i> , <b>2012</b> , 118, 5078-83	6.4	26
104	Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2478-83	2.2	25
103	Interrogation of a context-specific transcription factor network identifies novel regulators of pluripotency. <i>Stem Cells</i> , <b>2015</b> , 33, 367-77	5.8	24
102	Treatment of CD30-Expressing Germ Cell Tumors and Sex Cord Stromal Tumors with Brentuximab Vedotin: Identification and Report of Seven Cases. <i>Oncologist</i> , <b>2018</b> , 23, 316-323	5.7	23
101	Late Relapse of Testicular Germ Cell Tumors. <i>Urologic Clinics of North America</i> , <b>2015</b> , 42, 359-68	2.9	22
100	Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples. <i>European Urology Focus</i> , <b>2017</b> , 3, 590-598	5.1	21
99	Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and older. <i>Cancer</i> , <b>2013</b> , 119, 2574-81	6.4	21
98	DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy <b>2020</b> , 8,		20
97	Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma. <i>European Urology Focus</i> , <b>2018</b> , 4, 986-994	5.1	20
96	Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer. <i>Urology</i> , <b>2012</b> , 79, 156-9	1.6	20
95	Rare de novo germline copy-number variation in testicular cancer. <i>American Journal of Human Genetics</i> , <b>2012</b> , 91, 379-83	11	20
94	Evaluation of lymph node counts in primary retroperitoneal lymph node dissection. <i>Cancer</i> , <b>2010</b> , 116, 5243-50	6.4	20
93	Phase II trial of ixabepilone in patients with cisplatin-refractory germ cell tumors. <i>Investigational New Drugs</i> , <b>2007</b> , 25, 487-90	4.3	20
92	Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. <i>Journal of the National Cancer Institute</i> , <b>2007</b> , 99, 974-5; author reply 976-7	9.7	20
91	Risk of Vascular Toxicity with Platinum Based Chemotherapy in Elderly Patients with Bladder Cancer. <i>Journal of Urology</i> , <b>2016</b> , 195, 33-40	2.5	19
90	Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1563-1574	2.2	19
89	Mucinous Tubular and Spindle-Cell Carcinoma of the Kidney: Clinical Features, Genomic Profiles, and Treatment Outcomes. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, 268-274.e1	3.3	18
88	Long-term mortality in patients with germ cell tumors: effect of primary cancer site on cause of death. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2014</b> , 32, 26.e9-15	2.8	18

87	Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2017</b> , 35, 532.e7-532.e13	2.8	17
86	Clinical and Genetic Risk Factors for Adverse Metabolic Outcomes in North American Testicular Cancer Survivors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2018</b> , 16, 257-265	7.3	17
85	Characterizing recurrent and lethal small renal masses in clear cell renal cell carcinoma using recurrent somatic mutations. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2019</b> , 37, 12-17	2.8	17
84	Body mass index is associated with higher lymph node counts during retroperitoneal lymph node dissection. <i>Urology</i> , <b>2012</b> , 79, 361-4	1.6	16
83	Phase II trial of pegylated interferon-alpha 2b in patients with advanced renal cell carcinoma. <i>Clinical Genitourinary Cancer</i> , <b>2008</b> , 6, 25-30	3.3	16
82	Development and Validation of a Gene-Based Model for Outcome Prediction in Germ Cell Tumors Using a Combined Genomic and Expression Profiling Approach. <i>PLoS ONE</i> , <b>2015</b> , 10, e0142846	3.7	16
81	Clinical and Genome-wide Analysis of Cisplatin-induced Tinnitus Implicates Novel Ototoxic Mechanisms. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 4104-4116	12.9	15
80	Predicting Cardiovascular Disease Among Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy: Application of the Framingham Risk Score. <i>Clinical Genitourinary Cancer</i> , <b>2018</b> , 16, e761-e769	3.2	15
79	Germ cell tumors and associated hematologic malignancies evolve from a common shared precursor. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 6668-6676	15.9	15
78	Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 5913-5924	12.9	13
77	Treatment options for stage I nonseminoma. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3797-800	2.2	13
76	High-dose chemotherapy and stem cell transplantation for advanced testicular cancer. <i>Expert Review of Anticancer Therapy</i> , <b>2011</b> , 11, 1091-103	3.5	13
75	Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1553-1562	2.2	13
74	Rates of teratoma and viable cancer at post-chemotherapy retroperitoneal lymph node dissection after induction chemotherapy for good risk nonseminomatous germ cell tumors. <i>Journal of Urology</i> , <b>2015</b> , 193, 513-8	2.5	12
73	Update in germ cell tumours. <i>Current Opinion in Oncology</i> , <b>2015</b> , 27, 177-84	4.2	12
72	Contemporary lymph node counts during primary retroperitoneal lymph node dissection. <i>Urology</i> , <b>2011</b> , 77, 368-72	1.6	12
71	Impact of Teratoma on the Cumulative Incidence of Disease-Related Death in Patients With Advanced Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2329-2337	2.2	11
70	Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial. <i>Oncologist</i> , <b>2019</b> , 24, 1497-1501	5.7	11

69	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients.. <i>Cell</i> , <b>2022</b> , 185, 563-575.e11	56.2	11
68	Conventional-Dose versus High-Dose Chemotherapy for Relapsed Germ Cell Tumors. <i>Advances in Urology</i> , <b>2018</b> , 2018, 7272541	1.6	11
67	Salvage high-dose chemotherapy for germ cell tumors. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2015</b> , 33, 355-62	2.8	10
66	A review of second-line chemotherapy and prognostic models for disseminated germ cell tumors. <i>Hematology/Oncology Clinics of North America</i> , <b>2011</b> , 25, 557-76, viii -ix	3.1	10
65	Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial. <i>Cancer</i> , <b>2020</b> , 126, 5247-5255	6.4	10
64	Controversies in the Management of Clinical Stage I Seminoma: Carboplatin a Decade in-Time to Start Backing Out. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 837-840	2.2	10
63	Bilateral Testicular Germ Cell Tumors in the Era of Multimodal Therapy. <i>Urology</i> , <b>2017</b> , 103, 154-160	1.6	9
62	Follow-Up Management of Patients With Testicular Cancer: A Multidisciplinary Consensus-Based Approach. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2015</b> , 13, 811-22	7.3	9
61	Novel targets and therapies for metastatic renal cell carcinoma. <i>Oncology</i> , <b>2006</b> , 20, 1745-53; discussion 1756	1.8	9
60	Outcomes after resection of postchemotherapy residual neck mass in patients with germ cell tumors--an update. <i>Urology</i> , <b>2011</b> , 77, 655-9	1.6	8
59	Quality-adjusted survival with first-line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance). <i>Cancer</i> , <b>2020</b> , 126, 5311-5318	6.4	8
58	Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 2910-2919	12.9	8
57	Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. <i>Genome Medicine</i> , <b>2021</b> , 13, 96	14.4	8
56	Testicular Germ Cell Tumors Acquire Cisplatin Resistance by Rebalancing the Usage of DNA Repair Pathways. <i>Cancers</i> , <b>2021</b> , 13,	6.6	8
55	Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations. <i>BMC Urology</i> , <b>2020</b> , 20, 84	2.2	7
54	Good-risk-advanced germ cell tumors: historical perspective and current standards of care. <i>World Journal of Urology</i> , <b>2009</b> , 27, 463-70	4	7
53	Cellular Therapy During COVID-19: Lessons Learned and Preparing for Subsequent Waves. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 27, 438.e1-438.e6		7
52	State-of-the-Art Management of Germ Cell Tumors. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2018</b> , 38, 319-323	7.1	7

51	Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen. <i>Urology</i> , <b>2018</b> , 114, 133-138	1.6	6
50	Clinical Outcome of Patients with Fibrosis/Necrosis at Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Advanced Germ Cell Tumors. <i>Journal of Urology</i> , <b>2017</b> , 197, 391-397	2.5	6
49	Treatment of stage I seminoma: is it time to change your practice?. <i>Journal of Hematology and Oncology</i> , <b>2008</b> , 1, 22	22.4	6
48	Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2019</b> , 17, 459-468	7.3	6
47	Pelvic Lymph Node Dissection in Patients Treated for Testis Cancer: The Memorial Sloan Kettering Cancer Center Experience. <i>Urology</i> , <b>2016</b> , 95, 128-31	1.6	6
46	Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2101944	2.2	6
45	Histologic and Oncologic Outcomes Following Liver Mass Resection With Retroperitoneal Lymph Node Dissection in Patients With Nonseminomatous Germ Cell Tumor. <i>Urology</i> , <b>2018</b> , 118, 114-118	1.6	5
44	Hearing Loss in Adult Survivors of Childhood Cancer Treated with Radiotherapy. <i>Children</i> , <b>2018</b> , 5,	2.8	5
43	Outcomes in patients with clinical stage III NSGCT who achieve complete clinical response to chemotherapy at extraretroperitoneal disease site. <i>Urology</i> , <b>2012</b> , 79, 1079-84	1.6	5
42	Infectious complications from high-dose chemotherapy and autologous stem cell transplantation for metastatic germ cell tumors. <i>Biology of Blood and Marrow Transplantation</i> , <b>2008</b> , 14, 595-600	4.7	5
41	Beyond stage I germ cell tumors: current status regarding treatment and long-term toxicities. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2014</b> , e180-90	7.1	5
40	Outcomes After Multidisciplinary Management of Primary Mediastinal Germ Cell Tumors. <i>Annals of Surgery</i> , <b>2021</b> , 274, e1099-e1107	7.8	5
39	The experience of hearing loss in adult survivors of childhood and young adult cancer: A qualitative study. <i>Cancer</i> , <b>2020</b> , 126, 1776-1783	6.4	5
38	Relationship of Cisplatin-Related Adverse Health Outcomes With Disability and Unemployment Among Testicular Cancer Survivors. <i>JNCI Cancer Spectrum</i> , <b>2020</b> , 4, pkaa022	4.6	5
37	The approach to the patient with synchronous bilateral germ cell tumors: a lesson in oncologic prioritization. <i>Oncology</i> , <b>2010</b> , 24, 761-3	1.8	5
36	The Management of Advanced Germ Cell Tumors in 2016: The Memorial Sloan Kettering Approach. <i>Oncology</i> , <b>2016</b> , 30, 653-64	1.8	5
35	Germ Cell Tumor Molecular Heterogeneity Revealed Through Analysis of Primary and Metastasis Pairs. <i>JCO Precision Oncology</i> , <b>2020</b> , 4,	3.6	4
34	Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 1332-1337	2.2	4



33	Bevacizumab Monotherapy as Salvage Therapy for Advanced Clear Cell Renal Cell Carcinoma Pretreated With Targeted Drugs. <i>Clinical Genitourinary Cancer</i> , <b>2016</b> , 14, 56-62	3.3	4
32	Phase II trial of paclitaxel, ifosfamide, and cisplatin (TIP) for previously untreated patients (pts) with intermediate- or poor-risk germ cell tumors (GCT).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 336-336	2.2	4
31	Comprehensive Genomic Analysis of Metastatic Non-Clear-Cell Renal Cell Carcinoma to Identify Therapeutic Targets. <i>JCO Precision Oncology</i> , <b>2019</b> , 3,	3.6	4
30	Datasets for the reporting of neoplasia of the testis: recommendations from the International Collaboration on Cancer Reporting. <i>Histopathology</i> , <b>2019</b> , 74, 171-183	7.3	4
29	Surgical Management of Patients with Advanced Germ Cell Tumors Following Salvage Chemotherapy: Memorial Sloan Kettering Cancer Center (MSKCC) Experience. <i>Urology</i> , <b>2019</b> , 124, 174-178	1.6	4
28	High-dose radiation therapy is needed for intracranial control and long-term survival in patients with non-seminomatous germ cell tumor brain metastases. <i>Journal of Neuro-Oncology</i> , <b>2019</b> , 142, 523-528	1.8	3
27	Phase I/II Trial of Paclitaxel With Ifosfamide Followed by High-Dose Paclitaxel, Ifosfamide, and Carboplatin (TI-TIC) With Autologous Stem Cell Reinfusion for Salvage Treatment of Germ Cell Tumors. <i>Clinical Genitourinary Cancer</i> , <b>2015</b> , 13, 453-60	3.3	3
26	Reply to B.I. Rini et al. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, e286-e287	2.2	3
25	Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 6550-6558	12.9	3
24	Hematologic Malignancies Arising in Patients with Germ Cell Tumors: Secondary Somatic Differentiation of Hematopoietic Malignancies from Germ Cell Precursors. <i>Blood</i> , <b>2018</b> , 132, 87-87	2.2	3
23	Association of genomic alterations with cisplatin resistance (cisR) in advanced germ cell tumors (aGCT).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4510-4510	2.2	3
22	Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report. <i>Case Reports in Oncology</i> , <b>2021</b> , 14, 430-438	1	3
21	Solid and Hematologic Neoplasms After Testicular Cancer: A US Population-Based Study of 24 900 Survivors. <i>JNCI Cancer Spectrum</i> , <b>2020</b> , 4, pkaa017	4.6	2
20	The conundrum of clinical trials in adult germ-cell tumours. <i>Lancet Oncology, The</i> , <b>2013</b> , 14, 14-5	21.7	2
19	Reply to L.C. Pagliaro et al. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2327-8	2.2	2
18	The role of high-dose chemotherapy in the management of germ cell tumors. <i>Current Opinion in Oncology</i> , <b>2014</b> , 26, 284-93	4.2	2
17	Genome-wide association study of cisplatin-induced peripheral neuropathy (CIPN) in testicular cancer survivors.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4543-4543	2.2	2
16	RAS/MAPK Pathway Driver Alterations Are Significantly Associated With Oncogenic KIT Mutations in Germ-cell Tumors. <i>Urology</i> , <b>2020</b> , 144, 111-116	1.6	2

15	Four Cycles of Etoposide plus Cisplatin for Patients with Good-Risk Advanced Germ Cell Tumors. <i>Oncologist</i> , <b>2021</b> , 26, 483-491	5.7	2
14	High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab. <i>Molecular Cancer Research</i> , <b>2021</b> , 19, 1510-1521	6.6	2
13	Is high-dose chemotherapy effective in patients with relapsed or refractory germ cell tumors?. <i>Nature Reviews Urology</i> , <b>2008</b> , 5, 78-9		1
12	Phase I/II study of paclitaxel plus ifosfamide (TI) followed by high-dose paclitaxel, ifosfamide, and carboplatin (TIC) with autologous stem cell transplant (ASCT) for salvage treatment of germ cell tumors (GCT).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 4534-4534	2.2	1
11	Variation in protein-coding sequence and the genetic basis of cisplatin-induced toxicities among testicular cancer survivors (TCS) in the Platinum Study.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1537-1537 <sup>2.2</sup>		1
10	Thoracic Metastasectomy in Germ Cell Tumor Patients Treated With First-line Versus Salvage Therapy. <i>Annals of Thoracic Surgery</i> , <b>2021</b> , 111, 1141-1149	2.7	1
9	Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors. <i>Investigational New Drugs</i> , <b>2021</b> , 39, 1656-1663	4.3	1
8	Genitourinary Medical Oncology Expert Opinion Survey Regarding Treatment Management in the COVID-19 Pandemic. <i>Clinical Genitourinary Cancer</i> , <b>2021</b> , 19, e178-e183	3.3	1
7	Reply to L.H. Einhorn et al. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, e740-e740	2.2	0
6	Use of Medications for Treating Anxiety or Depression among Testicular Cancer Survivors: A Multi-Institutional Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2021</b> , 30, 1129-1138	4	0
5	Microwave ablation (MWA) for the treatment of a solitary, chemorefractory testicular cancer liver metastasis. <i>CardioVascular and Interventional Radiology</i> , <b>2015</b> , 38, 488-93	2.7	
4	Reply to L.H. Einhorn et al. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3074-3075	2.2	
3	Cisplatin Therapy Does Not Worsen Renal Function in Severe Antenatal Bartter Syndrome. <i>Case Reports in Nephrology and Dialysis</i> , <b>2017</b> , 7, 49-54	1.3	
2	Curing germ cell tumors after failure of high-dose chemotherapy: progress through clinical trials. <i>Nature Clinical Practice Oncology</i> , <b>2007</b> , 4, 508-9		
1	Epidemiology, Biology, and Genetics of Adult Male Germ Cell Tumors <b>2015</b> , 431-450		